UK Markets open in 1 min

Pixium Vision SA (0QVB.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
2.0500+1.5250 (+290.48%)
At close: 01:23PM BST

Pixium Vision SA

74 rue du Faubourg Saint-Antoine
Paris 75012
33 1 76 21 47 68

Full-time employees28

Key executives

NameTitlePayExercisedYear born
Dr. Bernard Gilly Ph.D.Exec. Chairman11.96kN/A1957
Mr. Lloyd DiamondCEO & Director401.02kN/A1968
Mr. Offer NonhoffChief Financial OfficerN/AN/AN/A
Mr. Guillaume BucChief Technology OfficerN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat bilndness, which replace the normal physiological function of the eye's photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the visual information to the brain via the optic nerve. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.

Corporate governance

Pixium Vision SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.